SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cardiome -- CRME
CRME 2.330-2.1%May 16 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (203)9/1/2007 12:35:00 PM
From: keokalani'nui  Read Replies (1) of 285
 
OK. I understand those risks. Thought at first I had missed some published adverse event. That aside, drawing inferences as you have is where money is saved or made.

I'm not suspicious of the calling for a panel to approve a (new) 'atrial specific' CV drug for use in the ER. The efficacy studies weren't all that large in any event, and we haven't heard much if anything from the 12-month saftey study. Therein is reason enough for being vigilant.

What would be the SoC comparator in an oral pivotal trial? Presumably to prevent AF recurrence after conversion. It would be useful to mine its history.

Thanks for the conversation.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News